Our market reports now include the latest updates on global tariffs, trade impacts, and evolving supply chain dynamics.
What is the Anticipated CAGR of the Glioblastoma Multiforme Market, and What Factors Will Drive It?
In recent years, the market size for glioblastoma multiforme has seen robust growth. The market is anticipated to expand from $2.50 billion in 2024 to $2.71 billion in 2025, demonstrating a compound annual growth rate (CAGR) of 8.3%. This notable growth during the historical period is due to a surge in glioblastoma multiforme cases, improved healthcare infrastructure, enhanced awareness, wider access to cutting-edge therapies, and an increasing elderly population.
Significant expansion is anticipated in the glioblastoma multiforme market over the next few years. The market is projected to reach $3.69 billion in 2029, with a compound annual growth rate (CAGR) of 8.1%. Factors driving the growth during the projected period include an uptick in brain and other nervous system cancers, broader adoption of surgical procedures, increased awareness, early disease diagnosis, and a rise in R&D work. Foreseen trends for the period include medical technology developments, advances in imaging techniques, tailor-made medicine, AI-aided diagnosis, and technological and scientific progress.
Download a free sample to assess the report’s scope and structure:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21191&type=smp
What External and Internal Drivers Are Contributing to the Growth of the Glioblastoma Multiforme Market?
The surge in brain disorder instances is predicted to propel the glioblastoma multiforme market in the future. Anything that alters the functions or structure of the brain, leading to cognitive, emotional, or physical issues, is a brain disorder. There’s an upswing in these conditions due to aspects like an aging populace, increased longevity, lifestyle factors, and greater diagnostic skills. Gaining insight into brain disorders aids the progression of glioblastoma multiforme (GBM) research, subsequently enhancing early detection, pioneering treatment methods, and improved outcomes for patients. Scientists can discover the genetic and molecular aspects contributing to GBM progression by examining neurological conditions. For example, Dementia Australia, a non-profit organization based in Australia, reported in February 2025 that roughly 433,300 Australians were living with dementia – a figure predicted to swell to 812,500 by 2054. Also, younger-onset dementia impacted around 29,000 people in 2025, and this number is projected to increase to 41,000 by 2054. Thus, the escalating instances of brain disorders will fuel the glioblastoma multiforme market’s growth.
What Segment Types Define the Glioblastoma Multiforme Market Structure?
The glioblastoma multiforme market covered in this report is segmented –
1) By Drug Class: Chemotherapy Agents, Temozolomide, Carmustine, Lomustine, Other Drug Classes
2) By Diagnostic Tools: Magnetic Resonance Imaging (MRI), Computed Tomography Scan (CT Scan), Biopsy, Other Diagnostic Tools
3) By Treatment Type: Surgery, Radiation Therapy, Chemotherapy, Immunotherapy, Tumor Treating Field Therapy, Other Treatment Types
4) By End-User: Hospitals, Cancer Research Institutes, Ambulatory Surgical Centers, Other End-Users
Subsegments:
1) By Chemotherapy Agents: Alkylating Agents, Platinum-Based Agents, Antimetabolites
2) By Temozolomide: Branded (Temodar), Generic Temozolomide
3) By Carmustine: Injectable Carmustine, Carmustine Wafers (Gliadel)
4) By Lomustine: Branded (Gleostine), Generic Lomustine
5) By Other Drug Classes: Targeted Therapy, Immunotherapy, Tumor-Treating Fields (TTF) Therapy
Request customized data on this market:
https://www.thebusinessresearchcompany.com/customise?id=21191&type=smp
Which Geographic Areas Hold the Strongest Growth Potential in the Glioblastoma Multiforme Market?
North America was the largest region in the glioblastoma multiforme market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the glioblastoma multiforme market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
What Long-Term Trends Are Transforming the Competitive Landscape of the Glioblastoma Multiforme Market?
Leading firms in the glioblastoma multiforme market are concentrating their efforts on pioneering cutting-edge treatment methods, like CAR T-cell therapies, to meet the unfulfilled healthcare requirements of severe cancer diseases. CAR T-cell therapy is a subtype of immunotherapy, which modifies patient’s T-cells for more effectively detecting and destroying cancerous cells. For example, Chimeric Therapeutics Limited, a biotech company from Australia, commenced a Phase IB clinical trial for CHM 1101 (CLXT CAR T) therapy in the battle against recurrent or progressive glioblastoma multiforme (GBM) in June 2023. The trial, held at multiple locations, is designed to assess the safety and effectiveness of the therapy, while also setting the recommended dose for Phase 2. The original Phase 1a outcomes demonstrated disease stability, and this trial aims to expand upon these findings to push further development. The company intends to use this data to plan a registration trial and solicit regulatory input.
View the full report here:
https://www.thebusinessresearchcompany.com/report/glioblastoma-multiforme-global-market-report
What Is the Definition of the Glioblastoma Multiforme Market?
Glioblastoma multiforme (GBM) is an aggressive and fast-growing brain tumor that originates in the glial cells of the brain. It is the lethal form of primary brain cancer, characterized by rapid proliferation and resistance to standard treatments.
Purchase the full report and get a swift delivery:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21191
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model